{"id":"W2741245320","doi":"10.1158/1538-7445.am2017-ct075","title":"Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Placebo; Hazard ratio; Oncology; Gastroenterology; Cancer; Immunotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002097076,0.001286297,0.001556734,0.0003681747,0.0004187785,0.0009730893,0.0008275132,0.001019515,0.006249877],"category_scores_gemma":[0.00140968,0.0003553089,0.002115531,0.0004362629,0.0007823209,0.0006253672,0.0004536638,0.00331327,0.0009399112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001073729,"about_ca_system_score_gemma":0.001431269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001027682,"about_ca_topic_score_gemma":0.002502719,"domain_scores_codex":[0.9991819,0.0005337679,0.00004635287,0.00009729187,0.00006772063,0.00007285101],"domain_scores_gemma":[0.9986169,0.0003733863,0.0002867158,0.0001021717,0.00009909995,0.0005217583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9330766,0.008777656,0.00599882,0.0006800376,0.002085337,0.00006332349,0.0000629288,0.001508981,0.01055515,0.00009425441,0.004801092,0.03229573],"study_design_scores_gemma":[0.6279351,0.3240039,0.03343486,0.00009529352,0.003925713,0.0002096241,0.00004306544,0.001645918,0.005495119,0.0001831351,0.002988436,0.00003981391],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864065,0.004424121,0.0003912188,0.0007066298,0.0002085577,0.0008634231,0.003777105,0.0000931685,0.003129224],"genre_scores_gemma":[0.9855015,0.001511321,0.0007846131,0.0008423168,0.0003034501,0.0008670625,0.007215182,0.00003336972,0.002941238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006249877,"threshold_uncertainty_score":0.02090794,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06454676551010405,"score_gpt":0.3935429647153974,"score_spread":0.3289961992052933,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}